Opendata, web and dolomites

IMMUcan SIGNED

Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IMMUcan project word cloud

Explore the words cloud of the IMMUcan project. It provides you a very rough idea of what is the project "IMMUcan" about.

biological    contractual    inclusive    tissues    checkpoints    immune    samples    breast    investigations    host    stool    generating    period    functioning    majority    independent    assembled    relevance    accessibility    data    cancers    tissue    treatment    interaction    reproducibility    edge    platform    framework    plan    technologies    biomarker    academic    inhibitors    academia    rationale    microbiome    single    understand    utilizing    population    peptidogenomics    lung    sops    saliva    trials    tumor    quality    biobank    cell    pursue    colorectal    follow    oncology    combination    rna    human    stored    clinical    immuno    sustainability    immunotherapy    predictive    expert    head    types    start    running    uniform    proposes    proofed    immunoprofiling    blood    seq    failures    workflow    cytoff    na    ve    processed    material    centralized    therapies    cutting    recruiting    tumour    database    centers    perform    ethical    ten    gastric    volumes    mobilize    analyze    patients    collection    industry    absence    iuml    immucan    neck   

Project "IMMUcan" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL 

Organization address
address: Avenue E. Mounier 83
city: Brussels
postcode: 1200
website: www.eortc.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 34˙937˙500 €
 EC max contribution 17˙830˙000 € (51%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2024-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL BE (Brussels) coordinator 7˙246˙773.00
2    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 2˙749˙727.00
3    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 1˙712˙880.00
4    CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS CH (LAUSANNE) participant 1˙460˙332.00
5    SIB INSTITUT SUISSE DE BIOINFORMATIQUE CH (GENEVE) participant 1˙323˙000.00
6    KING'S COLLEGE LONDON UK (LONDON) participant 765˙066.00
7    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 628˙320.00
8    UNIVERSITAT ZURICH CH (ZURICH) participant 573˙700.00
9    INSTITUT CURIE FR (PARIS) participant 410˙000.00
10    FORUM EUROPEEN DES PATIENTS (FPE) LU (LUXEMBOURG) participant 250˙000.00
11    FUNDACIO CENTRE DE REGULACIO GENOMICA ES (BARCELONA) participant 190˙200.00
12    THE UNIVERSITY OF BIRMINGHAM UK (BIRMINGHAM) participant 160˙000.00
13    LIGUE NATIONALE CONTRE LE CANCER FR (PARIS) participant 120˙000.00
14    CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD FR (LYON) participant 100˙000.00
15    WEIZMANN INSTITUTE OF SCIENCE IL (REHOVOT) participant 100˙000.00
16    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) participant 20˙000.00
17    INSTITUT JULES BORDET BE (BRUXELLES) participant 20˙000.00
18    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
19    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
20    DE DUVE INSTITUTE BE (BRUXELLES) participant 0.00
21    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
22    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
23    INSTITUT DE RECHERCHE PIERRE FABRESAS FR (BOULOGNE BILLANCOURT) participant 0.00
24    INSTITUT DE RECHERCHES INTERNATIONALES SERVIER FR (SURESNES) participant 0.00
25    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
26    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) participant 0.00
27    OWKIN FRANCE FR (PARIS) participant 0.00
28    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00

Map

 Project objective

IMMUcan proposes an inclusive and integrated European immuno-oncology platform. IMMUcan will access high-quality human biological material (tissue, blood, stool and saliva) and clinical data from patients with colorectal, lung, head & neck, breast, gastric cancers and immune checkpoints inhibitors failures. We have assembled a strong consortium with ten expert clinical centers, access to large volumes of the required tumor types. IMMUcan will mobilize the majority of academic trials running or expected to start recruiting patients during the project period. A centralized workflow for samples, via a state-of-the-art biobank will increase reproducibility as all tissues will be processed and stored in a uniform way, following proofed SOPs. The project will perform in depth immunoprofiling with cutting edge technologies including CyTOFF, single cell RNA-seq, peptidogenomics or microbiome analysis. IMMUcan will analyze the data in order to understand the host/tumour interaction in the absence of treatment (naïve population) and with treatment (patients in follow-up) to identify potential predictive biomarker for response to immunotherapy, or develop rationale for combination therapies. IMMUcan will provide an IT platform and legal/ethical contractual framework where participants from both academia and industry can pursue their own independent investigations utilizing the IMMUcan data and effectively testing and improving the functioning and relevance of the database. A sustainability plan will be developed to ensure the collection of follow-up data and the accessibility of the data platform. The use of the data generating throughout this project, for future research, will be supported.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IMMUCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IMMUCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More